Edgewise Therapeutics (EWTX) Competitors $16.88 +0.48 (+2.92%) As of 10:55 AM Eastern This is a fair market value price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock EWTX vs. LEGN, SRPT, TLX, ADMA, BPMC, VRNA, NUVL, AXSM, GRFS, and CYTKShould you be buying Edgewise Therapeutics stock or one of its competitors? The main competitors of Edgewise Therapeutics include Legend Biotech (LEGN), Sarepta Therapeutics (SRPT), Telix Pharmaceuticals Limited American Depositary Shares (TLX), ADMA Biologics (ADMA), Blueprint Medicines (BPMC), Verona Pharma (VRNA), Nuvalent (NUVL), Axsome Therapeutics (AXSM), Grifols (GRFS), and Cytokinetics (CYTK). These companies are all part of the "pharmaceutical products" industry. Edgewise Therapeutics vs. Legend Biotech Sarepta Therapeutics Telix Pharmaceuticals Limited American Depositary Shares ADMA Biologics Blueprint Medicines Verona Pharma Nuvalent Axsome Therapeutics Grifols Cytokinetics Edgewise Therapeutics (NASDAQ:EWTX) and Legend Biotech (NASDAQ:LEGN) are both medical companies, but which is the better stock? We will contrast the two companies based on the strength of their dividends, analyst recommendations, institutional ownership, risk, profitability, community ranking, earnings, valuation and media sentiment. Does the media refer more to EWTX or LEGN? In the previous week, Legend Biotech had 1 more articles in the media than Edgewise Therapeutics. MarketBeat recorded 8 mentions for Legend Biotech and 7 mentions for Edgewise Therapeutics. Legend Biotech's average media sentiment score of 1.25 beat Edgewise Therapeutics' score of 1.20 indicating that Legend Biotech is being referred to more favorably in the news media. Company Very Positive Positive Neutral Negative Very Negative Overall Sentiment Edgewise Therapeutics 3 Very Positive mention(s) 1 Positive mention(s) 0 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Legend Biotech 5 Very Positive mention(s) 0 Positive mention(s) 2 Neutral mention(s) 0 Negative mention(s) 0 Very Negative mention(s) Positive Is EWTX or LEGN more profitable? Edgewise Therapeutics has a net margin of 0.00% compared to Legend Biotech's net margin of -66.92%. Edgewise Therapeutics' return on equity of -26.83% beat Legend Biotech's return on equity.Company Net Margins Return on Equity Return on Assets Edgewise TherapeuticsN/A -26.83% -25.67% Legend Biotech -66.92%-29.69%-19.45% Do analysts recommend EWTX or LEGN? Edgewise Therapeutics presently has a consensus price target of $40.22, suggesting a potential upside of 138.30%. Legend Biotech has a consensus price target of $78.82, suggesting a potential upside of 126.65%. Given Edgewise Therapeutics' higher probable upside, equities analysts plainly believe Edgewise Therapeutics is more favorable than Legend Biotech.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Edgewise Therapeutics 0 Sell rating(s) 2 Hold rating(s) 7 Buy rating(s) 0 Strong Buy rating(s) 2.78Legend Biotech 0 Sell rating(s) 1 Hold rating(s) 11 Buy rating(s) 0 Strong Buy rating(s) 2.92 Which has stronger earnings & valuation, EWTX or LEGN? Edgewise Therapeutics has higher earnings, but lower revenue than Legend Biotech. Legend Biotech is trading at a lower price-to-earnings ratio than Edgewise Therapeutics, indicating that it is currently the more affordable of the two stocks. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioEdgewise TherapeuticsN/AN/A-$100.16M-$1.45-11.64Legend Biotech$627.24M10.18-$518.25M-$0.48-72.45 Which has more volatility and risk, EWTX or LEGN? Edgewise Therapeutics has a beta of 0.32, indicating that its stock price is 68% less volatile than the S&P 500. Comparatively, Legend Biotech has a beta of 0.21, indicating that its stock price is 79% less volatile than the S&P 500. Does the MarketBeat Community favor EWTX or LEGN? Legend Biotech received 50 more outperform votes than Edgewise Therapeutics when rated by MarketBeat users. However, 72.73% of users gave Edgewise Therapeutics an outperform vote while only 72.58% of users gave Legend Biotech an outperform vote. CompanyUnderperformOutperformEdgewise TherapeuticsOutperform Votes4072.73% Underperform Votes1527.27% Legend BiotechOutperform Votes9072.58% Underperform Votes3427.42% Do insiders & institutionals have more ownership in EWTX or LEGN? 70.9% of Legend Biotech shares are held by institutional investors. 24.1% of Edgewise Therapeutics shares are held by insiders. Comparatively, 0.0% of Legend Biotech shares are held by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term. SummaryLegend Biotech beats Edgewise Therapeutics on 9 of the 17 factors compared between the two stocks. Get Edgewise Therapeutics News Delivered to You Automatically Sign up to receive the latest news and ratings for EWTX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart EWTX vs. The Competition Export to ExcelMetricEdgewise TherapeuticsPharmaceutical IndustryMedical SectorNASDAQ ExchangeMarket Cap$1.76B$6.75B$5.51B$7.93BDividend YieldN/A3.05%5.11%4.22%P/E Ratio-11.217.3222.5518.49Price / SalesN/A239.19394.97102.66Price / CashN/A65.8538.1834.62Price / Book3.736.436.694.25Net Income-$100.16M$143.21M$3.22B$248.31M7 Day Performance9.60%1.24%1.11%1.12%1 Month Performance-16.15%6.09%3.59%3.68%1 Year Performance-11.21%-3.34%15.65%5.19% Edgewise Therapeutics Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)EWTXEdgewise Therapeutics3.2304 of 5 stars$16.88+2.9%$40.22+138.3%-8.6%$1.76BN/A-11.2160Upcoming EarningsAnalyst ForecastShort Interest ↑News CoveragePositive NewsLEGNLegend Biotech2.6303 of 5 stars$34.70+1.2%$78.82+127.1%-20.1%$6.37B$627.24M-36.531,070SRPTSarepta Therapeutics4.733 of 5 stars$61.51+1.8%$158.70+158.0%-50.7%$5.97B$1.90B49.21840Upcoming EarningsTLXTelix Pharmaceuticals Limited American Depositary SharesN/A$17.57-6.5%$22.00+25.2%N/A$5.94B$783.21M0.00N/AAnalyst RevisionNews CoverageHigh Trading VolumeADMAADMA Biologics1.4704 of 5 stars$24.51+12.1%$22.50-8.2%+265.0%$5.82B$426.45M87.54530Upcoming EarningsNews CoveragePositive NewsHigh Trading VolumeBPMCBlueprint Medicines2.5644 of 5 stars$88.51+1.0%$124.53+40.7%-2.0%$5.66B$508.82M-81.95640Earnings ReportAnalyst ForecastNews CoveragePositive NewsVRNAVerona Pharma2.8962 of 5 stars$68.83+5.1%$78.50+14.0%+366.5%$5.56B$42.28M-35.8530Earnings ReportAnalyst ForecastShort Interest ↓Analyst RevisionNews CoveragePositive NewsNUVLNuvalent1.8879 of 5 stars$75.20+2.3%$115.50+53.6%+11.4%$5.38BN/A-21.6740Upcoming EarningsPositive NewsAXSMAxsome Therapeutics4.8364 of 5 stars$107.24+0.9%$169.80+58.3%+52.2%$5.23B$385.69M-17.90380Upcoming EarningsAnalyst ForecastShort Interest ↓Positive NewsGRFSGrifols3.8957 of 5 stars$7.15-0.8%N/A+8.1%$4.92B$7.21B6.1126,300Short Interest ↓Positive NewsCYTKCytokinetics4.1729 of 5 stars$41.22+2.0%$79.13+92.0%-30.1%$4.91B$18.47M-7.66250Upcoming EarningsInsider Trade Related Companies and Tools Related Companies Legend Biotech Competitors Sarepta Therapeutics Competitors Telix Pharmaceuticals Limited American Depositary Shares Competitors ADMA Biologics Competitors Blueprint Medicines Competitors Verona Pharma Competitors Nuvalent Competitors Axsome Therapeutics Competitors Grifols Competitors Cytokinetics Competitors Top 10 Stock Comparisons Semiconductor Stocks Artificial Intelligence Stocks Growth Stocks Magnificent Seven Stocks Pharmaceutical Stocks Ecommerce Stocks Bitcoin Stocks Meme Stocks Cryptocurrency Stocks Cybersecurity Stocks This page (NASDAQ:EWTX) was last updated on 5/1/2025 by MarketBeat.com Staff From Our PartnersHow to invest in Elon Musk’s Optimus before its launchElon Musk is set to completely take over the AI industry with Optimus… A breakthrough AI-powered robot that El...InvestorPlace | SponsoredIs he more powerful than Trump? Is there anybody more powerful than Donald Trump right now? In a single tariff announcement, he wiped out n...Porter & Company | SponsoredTrump and Buffett Are Quietly Leading America’s Gold RevivalThe “Buffett Indicator” Predicts Gold Set To Dominate for Next Decade Each time the Buffett Indicator has...Golden Portfolio | SponsoredThis isn’t a trade war. It’s worse…Investigative Journalist Bombhsell: The Curse on the U.S Dollar Depleted retirement accounts? Meme coin inv...Stansberry Research | SponsoredElon Set to Shock the World by May 1st ?Tech legend Jeff Brown recently traveled to the industrial zone of South Memphis to investigate what he believ...Brownstone Research | SponsoredElon Musk’s next move from the Oval Office?No one is closer to President Trump than Tesla CEO Elon Musk. He's been dubbed Trump's "first buddy." Tr...Weiss Ratings | SponsoredTrump Treasure April 19Thanks to President Trump… A $900 investment across5 specific cryptos… Could gain 12,000% so quickly tha...Paradigm Press | SponsoredThey rigged the gameThe U.S. fired the first shot with 145% tariffs. Apple relies heavily on Chinese production. Tesla needs Ch...Investors Alley | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Edgewise Therapeutics, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Edgewise Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Buy EWTX Stock Free EWTX Stock Alerts